Phase II study of avelumab in multiple relapsed/refractory germ cell cancer

This study aimed to determine the efficacy and safety of avelumab, a PD-L1 inhibitor, in patients with GCTs.Methods In this phase 2 study, patients with multiple relapsed and/or refractory GCTs were treated with avelumab at a dose of 10  mg/kg administered biweekly until progression or unacceptable toxicity. The primary endpoint was 12-week progression-free survival (PFS). Fifteen evaluable patients had to be enrolled in the first cohort, and if
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research

Related Links:

ConclusionIn this analysis we were able to identify regions with significantly higher tumor incidence rates for both seminoma and non ‐seminoma which were specific for these two subtypes. Furthermore, trend analysis revealed a steady incidence rate for testicular cancer in Germany.
Source: Andrology - Category: Urology & Nephrology Authors: Tags: Original Article Source Type: research
Testicular germ cell tumors (TGCTs) are unique to that of most other solid tumors because they are highly curable in the metastatic setting. While the use of cisplatin-based chemotherapy continues to drive cure in this patient population, important improvements in the delivery of therapy, creation of risk-adjusted treatment paradigms, and salvage-therapy options have further enhanced survival as well. The future holds promise for a more multidisciplinary approach to care, through advancements in biochemical markers and a better understanding of how surgical and radiotherapy approaches can integrate into our existing management strategies.
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Evaluating 25 years of OGCT incidence data, the highest incidence rates and largest increases in incidence were seen in Eastern Asia. Future studies should focus on etiologic features that may account for geographic variation and increases in incidence of OGCT. PMID: 31303255 [PubMed - as supplied by publisher]
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Tags: Gynecol Oncol Source Type: research
This article reviews the current knowledge on high-dose chemotherapy (HDCT) and stem cell transplant for salvage treatment of patients with relapsed metastatic GCT. Furthermore, the authors attempt to dissect the controversy of using standard-dose versus high-dose therapy as initial salvage and identify patients who are most likely to benefit from HDCT and peripheral blood stem cell transplant. PMID: 31277738 [PubMed - in process]
Source: The Urologic Clinics of North America - Category: Urology & Nephrology Authors: Tags: Urol Clin North Am Source Type: research
Abstract Experience demonstrates multiple paths to cure for patients with clinical stage I testicular cancer. Because all options should provide a long-term disease-free rate near 100%, overall survival is no longer relevant in decision making, allowing practitioners to factor in quality of life, toxicity, cost, and impact on compliance. Surveillance for clinical stage I seminoma and clinical stage I nonseminoma has become the preferred option. The contrarian view is that a risk-adapted approach should persist, with surveillance for low-risk individuals and active therapy high-risk individuals. However, results ob...
Source: The Urologic Clinics of North America - Category: Urology & Nephrology Authors: Tags: Urol Clin North Am Source Type: research
Abstract Growing teratoma syndrome (GTS) is a rare clinical phenomenon in patients with nonseminomatous germ cell cancer defined by growing metastatic mass during ongoing or directly after completed chemotherapy with timely decreasing tumor markers and postpubertal teratoma exclusively after resection. GTS was first described in 1982, and few reports have been published. The limited number of studies and the resulting lack of exact knowledge about development, differentiation, and treatment of GTS leaves several clinical problems regarding treatment and follow-up unsolved. This review provides an overview of clini...
Source: The Medical Clinics of North America - Category: General Medicine Authors: Tags: Urol Clin North Am Source Type: research
In conclusion, this study brings new insights on the metabolic characteristics of TGCTs, showing alterations in the expression of proteins related with the Warburg effect, as well as associations of the hyper-glycolytic and acid-resistant phenotype with aggressive clinicopathological parameters.
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
ConclusionsAYA in the US experience disparities in cancer survival based on insurance status, independent of late stage of presentation. Patients age 26 ‐39 may be especially vulnerable to health outcomes associated with poor socioeconomic status, treatment disparities, and poor access to care.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
ConclusionsThe Male Reproductive Health Initiative (MRHI) is a newly established and rapidly growing global consortium of key opinion leaders in research, medicine, funding and policy agencies, and patient support groups that are moving forward the significant task of accomplishing the goals of the strategic roadmap.
Source: Andrology - Category: Urology & Nephrology Authors: Tags: Opinion Article Source Type: research
ConclusionOur results indicate that the analyzed hematological markers are associated with poor prognoses at diagnosis. Therefore, their use in daily clinical practice can be a valuable tool in the diagnosis and prognosis of patients with testicular germ cell tumors.ResumenIntroducciónEl sistema inmune ejerce un papel clave en la respuesta del organismo frente al cáncer. Existen diversos marcadores hematológicos que pueden influir en el pronóstico y supervivencia de los pacientes. El objetivo de este estudio es determinar su valor pronóstico en tumores testiculares de células germi...
Source: Actas Urologicas Espanolas - Category: Urology & Nephrology Source Type: research
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Germ Cell Tumors | Investigational New Drugs | Study | Toxicology